PharmGKB summary
Authors:
- 1 May 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 28 (5) , 127-137
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- PharmGKB summaryPharmacogenetics and Genomics, 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingClinical Pharmacology & Therapeutics, 2015
- Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral TherapyPLOS ONE, 2015
- Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trialHIV Research & Clinical Practice, 2015
- Evaluating the In Vitro Inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in Predicting Drug-Induced HyperbilirubinemiaMolecular Pharmaceutics, 2013
- Pharmacokinetics of an Increased Atazanavir Dose With and Without Tenofovir During the Third Trimester of PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Complicated Atazanavir-Associated Cholelithiasis: A Report of 14 CasesClinical Infectious Diseases, 2012
- Genetic Factors Influencing Severe Atazanavir‐Associated Hyperbilirubinemia in a Population with Low UDP‐Glucuronosyltransferase 1A1*28 Allele FrequencyClinical Infectious Diseases, 2010
- Multidrug Resistance 1 Polymorphisms and Trough Concentrations of Atazanavir and Lopinavir in Patients with HIVPharmacogenomics, 2007
- Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotypeHepatology, 2006